LOVFF (Cannara Biotech) LT-Debt-to-Total-Asset: 0.14 (As of Feb. 2026)

What is Cannara Biotech LT-Debt-to-Total-Asset?

Cannara Biotech LOVFF -4.84% 84 LT-Debt-to-Total-Asset is 0.14 as of Feb. 2026. GuruFocus rates LOVFF with a GF Score™ of 84/100 and a GF Value™ of $1.18 (Fairly Valued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cannara Biotech's long-term debt to total assests ratio for the quarter that ended in Feb. 2026 was 0.14.

Cannara Biotech's long-term debt to total assets ratio declined from Feb. 2025 (0.21) to Feb. 2026 (0.14). It may suggest that Cannara Biotech is progressively becoming less dependent on debt to grow their business.

Cannara Biotech (OTCPK:LOVFF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cannara Biotech LT-Debt-to-Total-Asset Related Terms

Cannara Biotech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Cannara Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannara Biotech LT-Debt-to-Total-Asset Chart

Cannara Biotech Annual Data

Trend

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Aug25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.22

0.37

0.28

0.25

0.17

Cannara Biotech Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25	Aug25	Nov25	Feb26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.21	0.20	0.17	0.15	0.14

84GF Score

Cannara Biotech Inc LOVFF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cannara Biotech LT-Debt-to-Total-Asset Calculation

Cannara Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Aug. 2025 is calculated as

LT Debt to Total Assets (A: Aug. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Aug. 2025 )	/	Total Assets (A: Aug. 2025 )
	=	20.499	/	122.234
	=	0.17

Cannara Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2026 is calculated as

LT Debt to Total Assets (Q: Feb. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Feb. 2026 )	/	Total Assets (Q: Feb. 2026 )
	=	18.48	/	133.212
	=	0.14

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.14 mean?

Cannara Biotech (LOVFF) has a LT-Debt-to-Total-Asset of 0.14 as of Feb. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cannara Biotech and its competitors.

Is Cannara Biotech's LT-Debt-to-Total-Asset too high?

Cannara Biotech's current LT-Debt-to-Total-Asset is 0.14. Overall, Cannara Biotech has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Cannara Biotech's LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Cannara Biotech's LT-Debt-to-Total-Asset of 0.14 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cannara Biotech and its competitors. Cannara Biotech's current LT-Debt-to-Total-Asset is 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cannara Biotech stock overvalued right now?

Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Fairly Valued. The stock's GF Value™ is $1.18, compared to a current price of $1.18 — trading right at its estimated fair value. The current LT-Debt-to-Total-Asset is 0.14. Cannara Biotech's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current LT-Debt-to-Total-Asset is 0.14 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cannara Biotech (LOVFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cannara Biotech stock appears to be undervalued. The current stock price of $1.18 is trading 0% below its estimated GF Value™ of $1.18. GuruFocus considers Cannara Biotech to be Fairly Valued.

Key valuation signals for LOVFF:

LT-Debt-to-Total-Asset: 0.14
GF Value™: $1.18 vs. price of $1.18 (0% below fair value)
GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cannara Biotech Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TSXV:RX TSX:CRDL XCNQ:GRIN XCNQ:AAWH.U XCNQ:JUSH TSX:MDP TSX:HLS TSX:OGI TSX:CWEB XCNQ:NVRS XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges 8CB0:Germany LOVE:Canada

Address 1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

84GF Score

Get the complete analysis for LOVFF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18

Price

$1.18

GF Value

View LOVFF Analysis

See LT-Debt-to-Total-Asset data for all stocks →